Holen Sie sich die Stockscreener-App
87.33
1.28%
1.10
Handel nachbörslich:
87.90
0.57
+0.65%
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
How sentiment analysis helps forecast Arcellx Inc.Swing Trade & Reliable Intraday Trade Plans - newser.com
Improved FDA Outlook for Lead CAR-T Therapy Could Be a Game Changer for Arcellx (ACLX) - Sahm
Trend analysis for Arcellx Inc. this weekJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
FY2025 EPS Estimates for Arcellx Cut by Cantor Fitzgerald - MarketBeat
Analyzing recovery setups for Arcellx Inc. investors2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Arcellx (ACLX): Assessing Valuation Following Regulatory Tailwinds and Late-Stage Progress for Lead CAR-T Therapy - Sahm
Arcellx (NASDAQ:ACLX) Rating Lowered to Hold at Cantor Fitzgerald - MarketBeat
Automated trading signals detected on Arcellx Inc.July 2025 Update & Verified Momentum Watchlists - newser.com
Using data filters to optimize entry into Arcellx Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com
Is Arcellx Inc. showing signs of accumulationWeekly Market Summary & Fast Entry High Yield Tips - newser.com
Arcellx assumed with a Neutral at Cantor Fitzgerald - TipRanks
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook - Yahoo Finance
Arcellx's (ACLX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
ACLX: Cantor Fitzgerald Assumes Coverage with Neutral Rating | A - GuruFocus
What analyst consensus says on Arcellx Inc. stockWeekly Gains Report & Reliable Intraday Trade Plans - newser.com
Arcellx Inc Stock Analysis and ForecastIndustrial Stocks Review & Free Exceptional Market Positioning - earlytimes.in
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insider Selling: Michelle Gilson Sells 5,946 Shares of Arcellx Inc (ACLX) - GuruFocus
Arcellx CFO Gilson sells $511k in ACLX stock - Investing.com
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx (NASDAQ:ACLX) Biggest Nasdaq Stocks Mirror Biotech Progress - Kalkine Media
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Could Analyst Optimism on Neurotoxicity Give Arcellx (ACLX) an Edge in CAR-T Competition? - Sahm
Will Arcellx Inc. see short term momentumEarnings Recap Summary & Growth Focused Stock Reports - newser.com
Published on: 2025-10-05 04:40:22 - newser.com
A Fresh Look at Arcellx (ACLX) Valuation Following Scotiabank’s Regulatory Optimism and CAR-T Therapy Developments - Sahm
Will Arcellx Inc. bounce back from current supportMarket Movers & Fast Entry High Yield Tips - newser.com
What moving averages say about Arcellx Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
BofA Securities Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $112 - 富途牛牛
Arcellx (NASDAQ:ACLX) Shares Up 4.3%Here's What Happened - MarketBeat
Arcellx CMO Heery sells $5851 in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx CMO Heery sells $5851 in ACLX stock - Investing.com India
What drives Arcellx Inc stock priceEx-Dividend Date Alerts & Budget Friendly Growth - earlytimes.in
Using portfolio simulators with Arcellx Inc. includedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Arcellx CMO Heery sells $993k in ACLX stock - Investing.com India
Arcellx CMO Heery sells $993k in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx (NASDAQ:ACLX) Insider Sells $993,167.52 in Stock - MarketBeat
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $121 - 富途牛牛
Atle Fund Management AB Sells 18,439 Shares of Arcellx, Inc. $ACLX - MarketBeat
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):